The Immune and Neuroinflammatory Strand of ADHD: When Inflammation Shapes Attention
Not all ADHD may have the same cause.
Part 1 of this series examined ADHD as a prefrontal energy disorder — a state in which the brain’s most expensive region runs on a thin fuel supply. This part examines a fundamentally different idea: that a subset of ADHD-like features is driven by the immune system — chronic neuroinflammation and microglial activation that degrade the same prefrontal, dopaminergic, and attentional circuits that primary ADHD affects through development.
The two ideas are not in competition. They describe different patients and different mechanisms, and telling them apart matters enormously for treatment.
The series separates what we know from what our research adds. Here, the established findings are the neuroinflammatory signal in ADHD Yokokura et al. (2021) and the shared pro-inflammatory elevation in ADHD and chronic fatigue (Quadt et al. 2024). A further piece — neuroinflammation in chronic fatigue itself — is reported but contested: one study found it (Nakatomi et al. 2014), a replication did not (Raijmakers et al. 2021). What our research adds is the same-root reading — that inflammation-driven energy failure may be a shared etiology, with the ADHD phenotype appearing when the compartment affected is the brain — which is a registered speculation, not an established finding.
1 The idea: inflammation degrading attention circuits
The classic picture of ADHD is developmental: the brain’s dopaminergic and prefrontal circuits were built with a particular configuration from childhood. But an ADHD-like presentation does not require a developmental cause. A later inflammatory process can degrade the very same circuits, producing the same symptoms through a different route.
The mechanism proposed is a cascade:
- Inflammation raises its markers. Elevated pro-inflammatory cytokines — notably IL-6 and TNF-alpha — are documented independently in both ADHD and chronic fatigue Dunn et al. (2019).
- Microglia activate. Activated microglia are the brain’s resident immune cells, and their activation is documented in ADHD (Yokokura et al. 2021) and in chronic fatigue (Nakatomi et al. 2014).
- Dopamine is depleted. Inflammation diverts the cofactor BH4 away from dopamine synthesis toward a different branch of its metabolism, and drives oxidative stress that damages dopaminergic terminals. The result is a lower dopamine supply in the same circuits that primary ADHD affects.
- Prefrontal function degrades. The result is an ADHD-like clinical phenotype — inattention, impulsivity, executive difficulty — in a person whose pre-illness neurodevelopment was intact.
The key claim: sustained neuroinflammation can be sufficient to produce ADHD-like features in people who did not have ADHD before. That claim is a registered research speculation, not an established finding.
2 The evidence
Four findings sharpen the case:
1. Neuroinflammation is documented in ADHD. Substantial evidence supports neuroinflammation in ADHD pathophysiology, including elevated pro-inflammatory cytokines in children with ADHD and microglial activation in post-mortem and imaging studies (Dunn et al. 2019). Positron-emission tomography has demonstrated reduced dopamine D1-receptor availability co-localized with microglial activation in ADHD — the two phenomena in the same brain (Yokokura et al. 2021).
2. Neuroinflammation is documented in chronic fatigue — but contested. One study reported substantial elevation in microglial-activation markers across six brain regions (Nakatomi et al. 2014), but a subsequent study using the same tracer found no such elevation (Raijmakers et al. 2021). The neuroinflammation foundation for the same-root model is therefore contested, not established; every downstream claim inherits this uncertainty.
3. The shared inflammatory signal. ADHD traits at age 9 predict doubled chronic-fatigue risk at age 18, and this association is mediated by the inflammatory marker IL-6 (Quadt et al. 2024). This is the single most direct piece of evidence linking the inflammatory state of ADHD to later fatigue — but it establishes a statistical mediation, not a proven mechanism.
4. Convergent pharmacology. Both ADHD and chronic fatigue respond to the same dopamine and noradrenaline reuptake inhibitors Eckey et al. (2025). This is consistent with a shared dopaminergic deficit in both, whether developmental or acquired.
3 The orexin-dopamine bridge
A further hypothesis in our paper links the inflammatory strand to ADHD’s dopamine deficit through orexin — the wakefulness-promoting peptide. Orexin neurons project to the ventral tegmental area, where they regulate dopamine firing. Deficiency in this system reduces prefrontal dopamine (brain fog) and mesolimbic reward (anhedonia) (Sakurai et al. 1998).
The relevance to ADHD is specific: the same 8.1% lower cerebral glucose metabolism seen in ADHD may reflect a shared hypothalamic orexin deficit, and our paper’s hypothesis proposes that low orexin tone links to low dopamine metabolite and worse attention scores. Direct human evidence now exists: a study of drug-naive children with ADHD found decreased serum orexin A levels compared to controls (Baykal et al. 2019). Because inflammation can suppress orexin neuron function (the pathway by which chronic low-grade neuroinflammation is proposed to drive fatigue), an inflammatory hit that suppresses orexin would further deplete the already-low prefrontal dopamine of an ADHD-affected brain — closing a second route from inflammation to ADHD-like features.
This is a registered speculation with low confidence — the full orexin-inflammation-dopamine-ADHD chain is an inference across literatures, and the direct human orexin-ADHD finding is serum-based and single-study. It is included here for completeness as a distinct mechanism our paper develops, not as an established finding.
4 The kynurenine-dopamine bridge
A second, more specific route from inflammation to dopamine depletion runs through the kynurenine pathway — the tryptophan-metabolism branch that inflammation (via IDO) pushes toward neuroactive metabolites. Two of its products are directly relevant to dopamine:
- Kynurenic acid is neuroprotective at the NMDA receptor but, at low concentrations, it also reduces striatal dopamine release — an animal finding that connects kynurenine overactivation directly to the dopamine deficit implicated in ADHD (Rassoulpour et al. 2005).
- The pathway’s overactivation in the brain consumes NAD+ — the same cofactor mitochondria need for ATP — raising the possibility that kynurenine load and mitochondrial dysfunction compound each other, with the prefrontal cortex (the most energetically expensive region) showing the first deficit.
In humans recovering from COVID, kynurenine-pathway activation correlates with objective cognitive impairment (Cysique et al. 2023), and mitochondrial-complex gene suppression accompanies COVID cognitive decline (Xu et al. 2025). A 2026 translational viewpoint in Brain, Behavior, and Immunity brings these together explicitly, proposing a shared neuroimmune framework linking Long Covid and ADHD through convergent mechanisms — frontal-striatal-hippocampal dysfunction, catecholamine neuroimmune dysregulation, kynurenine overactivation, and mitochondrial bioenergetic defects (Spanoghe et al. 2026). It also notes that some Long Covid patients report partial benefit from ADHD-targeted medications (methylphenidate, guanfacine, low-dose lithium, dexamfetamine), with pre-existing autonomic dysregulation and post-exertional malaise as limiting factors Fesharaki-Zadeh, Lowe, and Arnsten (2023).
This is a registered speculation: the kynurenic-acid-lowers-dopamine finding is animal data, and the unified framework is a viewpoint without primary data of its own. But it sharpens the mechanism in this article’s cascade — inflammation does not only divert BH4 away from dopamine synthesis; its kynurenine arm can also act directly on dopamine release. The off-label pharmacotherapy reports are clinical observation, not a treatment recommendation.
5 The same-root hypothesis
Taken together, these lines point to a proposal from our research — the same-root hypothesis: ADHD and chronic fatigue (along with other neuroinflammatory conditions) may share a common root cause — chronic inflammation driving mitochondrial dysfunction and energy failure — with the specific diagnosis determined by which tissues are affected. The causal chain is: inflammation → cytokine-mediated metabolic suppression → mitochondrial ATP deficit → brain energy failure (an ADHD phenotype when compartmentalized) or systemic energy failure (a fatigue phenotype when generalized).
Inflammation is the proposed primary driver; mitochondrial dysfunction is the mechanistic intermediate; symptom expression is determined by which tissues cross their energy threshold first.
This is a registered speculation with low confidence — a hypothesis to test, not an established finding. It is not the claim that all ADHD is inflammatory; it is the claim that a subset of ADHD-like features may be acquired and immune-driven.
6 Where a mechanism already has a dedicated article
Several adjacent mechanisms have dedicated articles in this blog:
- Why People with ADHD Get ME/CFS at Twice the Rate — the epidemiological bridge between ADHD and post-infectious fatigue.
- Your ADHD Is an Energy Problem — the energy-production argument this strand connects to.
- One Cofactor, Six Conditions, One Bottleneck — the BH4 cofactor that inflammation diverts away from dopamine synthesis.
7 The honest limits
This framework is explicitly speculative, with low certainty.
- The core neuroinflammation premise in chronic fatigue is contested — one study found it, a replication did not Raijmakers et al. (2021).
- No study has measured the same inflammatory and microglial panel simultaneously across ADHD, chronic fatigue, and healthy controls.
- The same-root hypothesis rests on cross-sectional and retrospective designs; no prospective study has tracked ADHD-like symptom emergence after an inflammatory trigger in a pre-illness-characterized cohort.
- The framework covers a subset of ADHD-like features, not the entire condition. Most ADHD is developmental and stable, not acquired.
- Even where inflammation is present, the causal direction is unresolved: inflammation could drive dopamine depletion, or chronic dopaminergic dysregulation could secondarily stress the immune system.
Convergence does not raise certainty above the weakest link. Until a multi-disease, prospective study exists, this is a research framework, not a finding.
8 The decisive experiment
The field needs a prospective test: track a cohort after an inflammatory trigger (e.g., a viral infection) and measure whether new-onset inattention and executive difficulty emerge alongside markers of neuroinflammation, in people with no prior ADHD history. The framework predicts that the severity of acquired ADHD-like features should track inflammatory markers and should improve when inflammation is treated.
If acquired inattention follows inflammation and reverses with anti-neuroinflammatory treatment, the same-root model is supported. If no new-onset ADHD-like features appear even in the presence of neuroinflammation, the model fails for that population.
9 What to take away
The immune and neuroinflammatory model does not claim that ADHD is an immune disease. It claims that a subset of ADHD-like features may be driven by inflammation and microglial activation — an immune process that can deplete dopamine and degrade the same prefrontal circuits that primary ADHD affects through development.
The encouraging part: if some ADHD-like features are immune-driven, they may be acquired and reversible — addressable by treating the inflammation rather than accepted as permanent wiring.
The honest part: this is a research framework, not a clinical recommendation. The neuroinflammation premise is contested, no screening is indicated, and no immunomodulatory treatment for ADHD-like features is established. The decisive prospective study has not been done.
This is Part 2 of a four-part series on the biology of ADHD. Part 1 covers the prefrontal-energy model and the multi-pathway treatment hypothesis. Part 3 explores the dopamine-Nrf2-NLRP3 axis. Part 4 asks when ADHD-like features are acquired and reversible. See the series landing page.
This article reflects research hypotheses from our documentation project. The immune and neuroinflammatory strand of ADHD is an active area of investigation with explicit, low confidence — not established clinical fact. Discuss any medical decision with a qualified clinician.